Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Leading Ascelia Pharma through the Covid-19 period

Dear all, we live in uncertain and unsettling times. The global Covid-19 pandemic has proven to be a harsh, merciless affliction to individuals, companies, organisations and entire countries. Almost every minute, we receive news about the rapid spread of this disease, with a rapidly increasing number of victims. As CEO of Ascelia Pharma, it is my responsibility to do my best to ensure that our community is safe and well. Together with my colleagues, I work meticulously to operate according to the regulations set by the authorities, and at the same time ensure that the company keeps on

THE FINNISH FINANCIAL SUPERVISORY AUTHORITY HAS APPROVED A SUPPLEMENT TO THE PROSPECTUS PREPARED FOR THE COMBINATION OF OUTOTEC AND THE METSO MINERALS BUSINESS

The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the combination of Outotec and the Metso Minerals BusinessThe Finnish Financial Supervisory Authority has today on March 30, 2020, approved a supplement to the Finnish language demerger prospectus (the “Prospectus”) relating to the combination of Outotec Oyj (“Outotec”) and Metso Corporation’s (“Metso”) Minerals business (the “Metso Minerals Business”). The supplement relates to the stock exchange releases of Outotec and Metso published on March 25, 2020 regarding a revision of the

UPM withdraws its outlook for 2020, operations performed during Q1 as expected

UPM-Kymmene Corporation       Stock Exchange Release (Inside Information)     30 March 2020 at 16:30 EET UPM withdraws its outlook for 2020, operations performed during Q1 as expected UPM withdraws its 2020 outlook and does not provide a new outlook until further notice. The business operations have performed during the first quarter as expected. However, the fast developing corona virus pandemic represents significant uncertainty for the rest of the year. UPM’s financial position is strong. UPM has net cash in the balance sheet and high liquidity reserves. Liquidity was further

Peab builds carbon dioxide neutral factory for Komatsu Forest in Umeå

Peab has been commissioned to build a new factory with an accompanying office building where the next generation of forestry machines will be manufactured. The customer is Komatsu Forest AB and the contract is worth SEK 650 million.Komatsu Forest will bring together manufacturing and development in their new facility. The factory is one of the largest investments in industrial Sweden right now, concentrated on sustainability and the Internet of Things. Construction of the factory will be carbon dioxide neutral, which will be achieved by an efficient energy supply with solar panels, modern

Episurf Medical to present at Digital Investor Forum on March 31, 2020

Episurf Medical (Nasdaq: EPIS B) will attend Digital Investor Forum on March 31 2020. The digital event is arranged by Redeye and the company will be represented by the CEO Pål Ryfors. The presentation will be available live at 15:40 on https://www.redeye.se/live/IF-31-mars. The presentation will also be available after the conference at Redeye’s website, as well as on the company’s website. For more information, please contact: Pål Ryfors, CEO, Episurf MedicalTel:+46 (0) 709 62 36 69Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to

SCA’s Nomination Committee proposes unchanged Directors’ fees

Due to the effects of the corona pandemic, SCA’s Nomination Committe has decided to withdraw its proposal on increased Directors’ fees. SCA’s Nomination Committee has decided to withdraw its proposal that the Annual General Meeting, to be held on Tuesday 31 March 2020, approve an increase of the Board of Directors’ fees (item 11 on the agenda). Instead, the Nomination Committee proposes no change in the Directors’ fees compared to 2019. All other proposals from the Nomination Committee to the Annual General Meeting remain unchanged.   For further information, please contact:

ABS Supports US COVID-19 Response

ABS Teams Assist Hospital Ships Activation(SAN DIEGO & NORFOLK) ABS made a key contribution to the nation’s COVID-19 response effort, helping ensure the readiness of two ABS-classed U.S. Navy hospital ships.ABS surveyors on the U.S. East and West coast helped the USNS Mercy and the USNS Comfort sail to provide urgently needed hospital beds in New York and Los Angeles.USNS Mercy was in her home port in San Diego making preparations for a large shipyard repair package scheduled to begin in April.  Her activation was advanced to support California’s request for the vessel to berth in Los

Changed decision on proposed dividend

The Board of Director’s assessment of the dividend level for 2019 remains unchanged. However, as a precaution and in order to better assess the consequences of the corona pandemic, the Board has decided to withdraw its proposal to the Annual General Meeting with regard to the dividend payout. The Board intends to call for an extraordinary General Meeting later in the year for a resolution on dividend payout. SCA’s financial position is strong, both in terms of equity as well as liquidity. The Board of Director’s assessment is that the former proposal on dividend payout would not

Stena Line fights to help ensure vital UK & Irish supply lines stay open

As the impact of the Coronavirus tightens its grip on everyday life across Europe, ferry company Stena Line has moved to reassure freight and travel customers that it is taking every precaution possible to help ensure the safety of customers and employees, whilst maintaining the supply lines for vital medical goods and food supplies. In the last few weeks Stena Line’s European business has been impacted significantly by COVID-19, but despite crippling trading circumstances, the biggest ferry company in Europe remains resolute in its determination to keep services going in strict

BioStock: Cereno Scientific delays start of phase II trial

Today, Cereno Scientific announced that they have postponed the start of their phase II trial for the main compound CS1 in thrombosis prevention. For the time being, the start has been moved from mid 2020 to late 2020, but the company is open to the need for further adjustments depending on the development of the ongoing coronavirus outbreak.Read the full article at biostock.se: https://www.biostock.se/en/cereno-scientific-delays-start-of-phase-ii-trial/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se 

Addnode Group provides update on corona pandemic impact, withdraws dividend proposal and announces cost savings measures

March 30, 2020, StockholmAlthough Addnode Group believes that the direct financial effects during the first quarter of 2020 will be limited, Addnode Group has identified a need to manage future effects on our operations as a result of the corona pandemic. At present, it is not possible to determine how large or long-lasting the corona pandemic effect is. Revoked dividend proposal Addnode Group has a strong financial position, but as a consequence of the uncertainty due to the corona pandemic, the Board of Addnode Group AB (publ) has decided to withdraw the previously announced

Bambuser publishes prospectus regarding the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. The prospectus regarding Bambuser AB’s (”Bambuser” or the ”Company”) rights issue of approximately SEK 101,1 million has today, 30 March 2020, been approved and registered by the Swedish Financial Supervisory Authority, and is available on

Bergs Timber restructures the Swedish sawmill business

A strategic review of the Swedish sawmill business has been carried out during the winter in order to create opportunities for long term profitability. The plan clearly indicates the potential to concentrate efforts in development and investments to three of the today’s four sawmills. In light of this plan, the Board of Directors of Bergs Timber has decided to immediately initiate discussion with the unions to close Gransjö sawmill. The sawmilling business will cease as soon as possible and the remaining business during the autumn 2020. The closure will affect about 45 employees. ”We

Bergs Timber postpones the annual general meeting and withdraws the proposed dividend

The Board of Directors of Bergs Timber AB has today, as a result of the spread of the corona virus, taken the decision to postpone the annual general meeting to a later date. Bergs Timber will publish an invitation to the annual general meeting no later than four weeks prior to the new date. The annual general meeting will be held, at the latest, on June 30 2020 in accordance with existing legislation. The Board of Directors has decided to withdraw the proposed dividend of SEK 0.04 per share, in total approximately SEK 14 million. The board´s decision has been taken in light of the

Mehiläinen Yhtiöt Oy supplements the tender offer document dated 8 January 2020 regarding the public cash tender offer for all shares in Pihlajalinna Plc

THIS STOCK EXCHANGE RELEASE MAY NOT BE RELEASED, PUBLISHED OR OTHERWISE DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FOR FURTHER INFORMATION, PLEASE SEE SECTION ENTITLED “IMPORTANT INFORMATION” BELOW. Mehiläinen Yhtiöt Oy supplements the tender offer document dated 8 January 2019 regarding the public cash tender offer for all shares in

The Nomination Committee proposes unchanged ordinary directors’ fees for 2020

As an act of solidarity in these times, the Nomination Committee proposes unchanged ordinary directors’ fees to the members of the Board of Directors.In light of this, the Nomination Committee will withdraw its proposal on increased fees to the Board of Directors. Instead, the Nomination Committee proposes unchanged ordinary fees to the members of the Board of Directors, which means SEK 740,000 to the Chairman of the Board, SEK 260,000 to the Vice Chairman and SEK 160,000 to each of the other Board members. Anders Oscarsson, Head of Equity & Head of Corporate Governance at AMF and a

Calliditas moves its Annual General Meeting 2020 to June 25

Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that due to the recent Covid-19 pandemic, the Company has decided to move its Annual General Meeting 2020 to June 25, 2020.The Annual Report for 2019 is expected to be published on April 28, 2020. The information was sent for publication, through the agency of the contact persons set out above, on March 30, 2020 at 2:00 p.m. CET. For further information, please contact: Renée Aguiar-Lucander, CEO, Calliditas Email: renee.lucander@calliditas.com Telephone: +46 722 52 10 06 Mikael Widell, Head of Communications

Aker Solutions Secures Brownfield Services Contract in Brunei

March 30, 2020 - Aker Solutions, in a joint venture with PTAS Sdn Bhd, has signed a five-year agreement to provide offshore maintenance and modification services to Brunei Shell Petroleum (BSP). Scope of work covers maintenance and upgrades to maintain production levels for more than 200 offshore assets. The name of the new entity is PTAS Aker Solutions Sdn Bhd. The joint venture will ensure continuity of delivery to BSP and has a strong local execution capability, combined with the full value of Aker Solutions’ international expertise. The work will be managed from PTAS Aker

Vicore submits clinical trial application for phase II trial with C21 in IPF

Gothenburg, March 30, 2020 – Vicore Pharma, a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces submission of the clinical trial application (CTA) for a proof-of-concept study with its proprietary compound C21 in patients with IPF (idiopathic pulmonary fibrosis) to the UK regulatory agency MHRA.The phase II clinical study in patients with IPF will be a six months single arm open label study which will compare the effect of C21 to the well documented linear decline of lung function in untreated patients. It will also be possible to,

OssDsign receives regulatory approval and prepares for launch in Japan

OssDsign AB (publ) today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval of OssDsign Cranial PSI for the Japanese market. OssDsign plans to launch OssDsign Cranial PSI in Japan together with a national distribution partner immediately following formal reimbursement approval which is expected within the next two quarters.As previously communicated, OssDsign has been pursuing a regulatory application in Japan since June 2019. The recent notice of regulatory approval from the PMDA is highly significant for OssDsign as the Japanese market for

COVID-19’s Effects on Stille

Stille AB (publ) informs about how the company is affected by the COVID-19 outbreak.After the publication of the year-end report on the 20th of February, uncertainty relating to the COVID-19 outbreak has increased. Changed priorities within the healthcare system, and actions to slow the spread of the virus is increasingly affecting the business. In line with the increased number of cases, the healthcare system is realigning their focus from surgery to intensive care, which has a considerable impact on the market’s demand for Stille’s products. Because of this reason, Stille believes that

InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2019

March 30, 2020 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2019. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/category/annual-reports/.The printed Annual Report is mailed to shareholders and other stakeholders who specifically request it. Send request to info@indexpharma.com, or by mail to InDex Pharmaceuticals Holding AB (publ), Tomtebodavägen 23a, 171 77 Stockholm.   For more information: Peter Zerhouni, CEOPhone: +46 8 508 847 35E-mail: peter.

SSAB to initiate employer-employee negotiations in its Finnish operations

SSAB has decided to initiate employer-employee negotiations concerning temporary layoffs in its Finnish operations following weakened market conditions as a result of the Covid-19 pandemic. The negotiations apply to SSAB Group’s personnel in Finland, excluding subsidiaries Ruukki Construction and Tibnor.The exact number of employees affected as well as the lengths of the temporary lay-offs will be decided in the negotiations. Any temporary layoffs would begin in week 16 at the earliest. For more information, please contactAtte Kaksonen, Press Officer, Finland, atte.kaksonen @ ssab.com,

There are no items matching the current filter
There are no more items matching the current filter
Back to top